Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00290745 · ClinicalTrials.gov registry record · Phase 1
Tamoxifen or Letrozole in Treating Women With Ductal Carcinoma in Situ
A Phase 1 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 1
- Development phase
- 79
- Enrollment target
NCT00290745 is a Phase 1 study that has completed, run by University of California, San Francisco. The registered enrollment target is 79 participants.
The verdict
NCT00290745, a Phase 1 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 79 participants
- Enrollment target
Study Summary
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen or letrozole may fight breast cancer by blocking the use of estrogen by the tumor cells or by lowering the amount of estrogen the body makes. PURPOSE: This clinical trial is studying how well tamoxifen or letrozole work in treating women with ductal carcinoma in situ.
Interventions
- DRUG letrozole
- PROCEDURE conventional surgery
- DRUG tamoxifen citrate
- PROCEDURE neoadjuvant therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 79 participants |
| Start Date | 2002-02-19 |
| Est. Completion | 2011-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00290745
The ClinicalTrials.gov registry entry for NCT00290745 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 79 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which letrozole is the first listed.
NCT00290745 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00290745 about?
NCT00290745 is a clinical study titled "Tamoxifen or Letrozole in Treating Women With Ductal Carcinoma in Situ". RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen or letrozole may fight breast cancer by blocking the use of estrogen by the tumor cells or by lowering the amount of estrogen the body makes. PURPOSE: This clinical trial is studying how well tamoxifen ...
What is the current status of trial NCT00290745?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 79 participants. The study started on 2002-02-19. Estimated completion is 2011-06-30.
What interventions are being tested in trial NCT00290745?
The interventions under investigation include: letrozole (DRUG), conventional surgery (PROCEDURE), tamoxifen citrate (DRUG), neoadjuvant therapy (PROCEDURE).
Who is sponsoring clinical trial NCT00290745?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.